Premium
Cyclic guanosine monophosphate phosphodiesterase activity in human gingival carcinoma
Author(s) -
Spoto Giuseppe,
Fioroni Massimiliano,
Rubini Corrado,
Contento Alessandro,
Di Nicola Maurizio,
Forcella Sabrina,
Piattelli Adriano
Publication year - 2003
Publication title -
journal of oral pathology and medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.887
H-Index - 83
eISSN - 1600-0714
pISSN - 0904-2512
DOI - 10.1034/j.1600-0714.2003.00083.x
Subject(s) - cyclic guanosine monophosphate , phosphodiesterase , guanosine , lymph node , carcinoma , pde10a , enzyme , endocrinology , medicine , guanosine monophosphate , second messenger system , basal cell , chemistry , pathology , biochemistry , nucleotide , nitric oxide , gene
Background: Cyclic guanosine monophosphate (cGMP) is an essential second messenger metabolized by phosphodiesterases (PDEs). Objectives: We looked for a possible correlation of PDE activities in human oral squamous cell carcinoma (OSCC) with and without lymph node metastases. Materials and methods: The analysis of phosphodiesterase activity and the cGMP assay were done by reverse‐phase HPLC on samples of fresh or frozen gingival tissues. Analysis of cGMP was confirmed with the enzyme‐linked immunoabsorption assay. Results and conclusions: cGMP PDE activity was 34.92 ± 7.17 SD, 12.89 ± 4.43 SD, and 35.88 ± 8.76 SD (nmols/mg of protein), respectively, in controls, samples without lymph node involvement (N − ), and specimens with lymph node metastases (N + ). cGMP values were 1.97 ± 0.63 SD, 3.30 ± 1.47 SD, and 3.49 ± 1.47 SD (nmols/mg of protein). Our data support the hypothesis of a role for cGMP and PDE in the progression of OSCC.